Novel Approaches for Oral Insulin Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novel Approaches for Oral Insulin Delivery
The authors review various oral drug delivery systems that have been explored to increase patient compliance for insulin.


Pharmaceutical Technology
Volume 33, Issue 7

64. Leon-Bay, "N-acylated Alpha-Amino Acids as Novel Oral Delivery Agemts for Proteins," J Med Chem. 38, 4263–4269 (1995).

65. S. Milstein, "Partially Unfolded Proteins Efficiently Penetrate Cell Membranes- Implications for Oral Drug Delivery," J Controlled Release 53, 259–267 (1998).

66. J. Still and R. McAllister, "Effects of Orally Active Modified Insulin in TypeI Diabetic Patients," Clinical Pharmacol. Ther. 69 (2), (2001).

67. L.L. Chang, "Immunohistochemical Localization of Insulin Degrading Enzyme along the Rat Intestine, in the Human Colon Adenocarcinoma Cell Line (Caco-2) and in Human Ileum," J. Pharm Sci. 86, 116–119 (1997).

68. Y. Li, Z. Shao, and A.K. Mitra, "Dissociation of Insulin Oligomers by Bile Salt Micelles and Its Effect on Alpha-Chymotrypsin-Mediated Proteolytic Degradation," Pharm Res. 9 (7), 864–869. (1992).

69. R.J. Schilling and A.K. Mitra, "Intestinal Mucosal Transport of Insulin," Int. J. Pharm. 62, 53–64 (1990).

70. M. Bendayan et al., "Morpho-cytochemical and Biochemical Evidence for Insulin Absorption by the Rat Ileal Epithelium," Diabetologia. 33 (4), 197–204 (1990).

71. M. Bendayan et al., "Biochemical and Morpho-cytochemical Evidence for the Intestinal Absorption of Insulin in Control and Diabetic Rats. Comparison between the Effectiveness of Duodenal and Colon Mucosa," Diabetologia. 37 (2), 119–126 (1994).

72. J.J. Bergeron et al., "Polypeptide Hormone Receptors In Vivo: demonstration of Insulin Binding to Adrenal Gland and Gastrointestinal Epithelium by Quantitative Radioautography," J. Histochem. Cytochem. 28 (8), 824–835 (1980).

73. D.J. Pillion, V. Ganapathy, and F.H. Leibach, "Identification of Insulin Receptors on the Mucosal Surface of Colon Epithelial Cells," J. Biol Chem. 260 (9), 5244–5247. (1985).

74. R.L. Gingerich et al., "Identification and Characterization of Insulin Receptors in Basolateral Membranes of Dog Intestinal Mucosa," Diabetes 36 (10), 1124–1129 (1987).

75. R. Greenwood and A. Al-Achi, "Human Insulin Diffusion Profile through a Layer of Caco-2 Cells," Drug Dev. Ind. Pharm. 23, 221–224 (1997).

76. J. Brange and L. Langkjoer, "Insulin Structure and Stability," in Stability and Characterization of Protein and Peptide Drugs: Case Histories, Y.J. Wang and R. Pearlman, Eds. ( Plenum Press, New York, NY, 1993).

77 . O.L. Johnson, "Formulation of Proteins for Incorporation into Drug Delivery Sytems," in Protein Formulation and Delivery, E.J. McNally, Ed. (Marcel Dekker, New York, NY, 2000).

78. R. Pearlman and T.H. Nguyen, "Analysis of Protein Drugs," in Peptide and Protein Drug Delivery, V.H.L. Lee, Ed. (Marcel Dekker, New York, NY, 1991).

79. H. Hoffman, "Analytical Methods and Stability Testing of BioPharmaceuticals," in Protein Formulation and Delivery, E.J. McNally, Ed. (Marcel Dekker, New York, NY, 2000).

80. P.G. Shao and L.C. Bailey, "Porcine Insulin Biodegradable Polyester Microspheres: Stability and In Vitro Release Characteristics," Pharm Dev Technol. 5 (1), 1–9. (2000).

81. M.J. Pikal and D.R. Rigsbee, "The Stability of Insulin in Crystalline and Amorphous Solids: Observation of Greater Stability for the Amorphous Form," Pharm Res. 14 (10), 1379–1387. (1997).

82. R.T. Forbes et al., "Water Vapor Sorption Studies on the Physical Stability of a Series of Spray-Dried Protein/Sugar Powders for Inhalation," J. Pharm Sci. 87 (11), 1316–1321. (1998).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here